{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:31:03Z","timestamp":1762086663097,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.pharma.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T10:03:09Z","timestamp":1561629789000},"page":"394-417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a new stability indicating method for the simultaneous separation of voriconazole from its impurities along with sodium benzoate used as a preservative in a powder for oral suspension"],"prefix":"10.1016","volume":"77","author":[{"given":"A.","family":"Elleuch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Louati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Turki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Khalfallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Safta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2019.04.005_bib0210","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.41.11.2492","article-title":"A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei","volume":"41","author":"Sanati","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0215","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","article-title":"Organism-dependant fungicidal activities of azoles","volume":"42","author":"Manavathu","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0220","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.40.8.1948","article-title":"In vitro studies of two triazole antifungal agents (voriconazole [UK-104,496] and fluconazole) against Candida species","volume":"40","author":"Barry","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0732-8893(98)00005-4","article-title":"In vitro activity of voriconazole against Candida species","volume":"31","author":"Kauffman","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.pharma.2019.04.005_bib0230","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1128\/JCM.39.9.3254-3259.2001","volume":"39","author":"Pfaller","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pharma.2019.04.005_bib0235","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/AAC.41.3.575","article-title":"In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection","volume":"41","author":"Ruhnke","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0240","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.43.6.1463","article-title":"In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients","volume":"43","author":"Hoban","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0245","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1128\/AAC.43.1.169","article-title":"In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa","volume":"43","author":"Pfaller","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0250","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/JCM.36.1.198-202.1998","article-title":"In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pharma.2019.04.005_bib0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/42.1.91","article-title":"In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B","volume":"42","author":"Oakley","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0260","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/46.2.229","article-title":"A comparative study of the in vitro susceptibilities of clinical and laboratory selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH-56592)","volume":"46","author":"Manavathu","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0265","first-page":"573","article-title":"In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species","volume":"17","author":"Clancy","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pharma.2019.04.005_bib0270","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1128\/JCM.37.12.3946-3951.1999","article-title":"Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species","volume":"37","author":"Arikan","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pharma.2019.04.005_bib0275","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/JCM.39.3.954-958.2001","article-title":"In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi","volume":"39","author":"Espinel-Ingroff","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pharma.2019.04.005_bib0280","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","article-title":"In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum","volume":"44","author":"Li","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/43.1.149","article-title":"Comparative in vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum","volume":"43","author":"Cuenca-Estrella","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0290","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1128\/AAC.45.7.2151-2153.2001","article-title":"In vitro activities of four novel triazoles against Scedosporium spp","volume":"45","author":"Carrillo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0295","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/48.6.919","article-title":"In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole, and voriconazole","volume":"48","author":"Gomez-Lopez","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharma.2019.04.005_bib0300","unstructured":"Chem Axon: software solutions and service for chemistry and biology, July 22\u201325, 2018."},{"key":"10.1016\/j.pharma.2019.04.005_bib0305","unstructured":"Chembl Molecule EMBL-European Bio-informatics Institute."},{"key":"10.1016\/j.pharma.2019.04.005_bib0310","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/jaoac\/89.4.960","article-title":"Comparison of microbiological and UV-spectrophotometric assays for determination of voriconazole in tablets","volume":"89","author":"Adams","year":"2006","journal-title":"J AOAC Int"},{"issue":"2","key":"10.1016\/j.pharma.2019.04.005_bib0315","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jchromb.2004.10.069","article-title":"Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique","volume":"814","author":"Egle","year":"2005","journal-title":"J Chromatogr B"},{"issue":"6","key":"10.1016\/j.pharma.2019.04.005_bib0320","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00007691-200412000-00011","article-title":"Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry","volume":"26","author":"Keevil","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"9","key":"10.1016\/j.pharma.2019.04.005_bib0325","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bmc.383","article-title":"Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed phase column","volume":"18","author":"Pehourcq","year":"2004","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.pharma.2019.04.005_bib0330","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jchromb.2007.01.021","article-title":"Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection","volume":"852","author":"Chhun","year":"2007","journal-title":"J Chromatogr B"},{"issue":"2","key":"10.1016\/j.pharma.2019.04.005_bib0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1570-0232(02)00344-6","article-title":"Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry","volume":"776","author":"Zhou","year":"2002","journal-title":"J Chromatogr B: Anal Technol Biomed Life Sci"},{"issue":"11\u201312","key":"10.1016\/j.pharma.2019.04.005_bib0340","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/BF02467448","article-title":"Direct resolution of a new antifungal agent, voriconazole (UK-109,496) and its potential impurities, by use of coupled achiral-chiral high-performance liquid chromatography","volume":"47","author":"Ferretti","year":"1998","journal-title":"Chromatographia"},{"issue":"3","key":"10.1016\/j.pharma.2019.04.005_bib0345","first-page":"254","article-title":"Determination of voriconazole and its degradation products in pharmaceutical formulations using high-performance liquid chromatography with ultra-violet detection","volume":"5","author":"Badr Idin","year":"2010","journal-title":"Eurasian J Anal Chem"},{"key":"10.1016\/j.pharma.2019.04.005_bib0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1365\/s10337-009-1082-3","article-title":"LC stability studies of voriconazole and structural elucidation of its major degradation product","volume":"69","author":"Adams","year":"2009","journal-title":"Chromatographia"},{"issue":"2","key":"10.1016\/j.pharma.2019.04.005_bib0355","first-page":"79","article-title":"Separation of the voriconazole stereoisomers by capillary electrophoresis and liquid chromatography","volume":"4","author":"Owens","year":"1999","journal-title":"Enantiomer"},{"issue":"4","key":"10.1016\/j.pharma.2019.04.005_bib0360","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3797\/scipharm.1204-24","article-title":"A validated stability indicating liquid chromatographic method for determination of degradation impurities and diastereomer in voriconazole tablet","volume":"80","author":"Shaikh","year":"2012","journal-title":"Sci Pharm"},{"issue":"3","key":"10.1016\/j.pharma.2019.04.005_bib0365","first-page":"e35084","article-title":"An overview on the effects of sodium benzoate as a preservative in food products","volume":"3","author":"Shahmohannadi","year":"2016","journal-title":"Biotech Health Sci"},{"key":"10.1016\/j.pharma.2019.04.005_bib0370","unstructured":"European Pharmacopeia 9th edition, 2017. EDQM. European Advice."},{"key":"10.1016\/j.pharma.2019.04.005_bib0375","unstructured":"International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. ICH Validation of analytical procedures: text and methodology Q2 (R1). [Accessed November 2005. Available: https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf\/]."},{"issue":"4","key":"10.1016\/j.pharma.2019.04.005_bib0380","first-page":"205","article-title":"Guide de validation analytique, rapport d\u2019une commission SFSTP, m\u00e9thodologie","volume":"2","author":"Caporal-Gautier","year":"1992","journal-title":"S.T.P. Pharma Prat"},{"year":"2005","series-title":"Limite de d\u00e9tection et de quantification. Validation de la m\u00e9thode dans l\u2019analyse des produits pharmaceutiques. Une guide de bonnes pratiques","author":"Ermer","key":"10.1016\/j.pharma.2019.04.005_bib0385"},{"key":"10.1016\/j.pharma.2019.04.005_bib0390","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0731-7085(90)80090-C","article-title":"A practical approach to method validation in pharmaceutical analysis","volume":"86","author":"Carr","year":"1990","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2019.04.005_bib0395","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0731-7085(02)00047-X","article-title":"Development of validated stability indicating assay methods-Critical review","volume":"28","author":"Bakshi","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2019.04.005_bib0400","unstructured":"Stability testing of new drug substances and products. ICH Q1A (R2) Guidelines. [Accessed 2003. Available on: https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q1A_R2\/Step4\/Q1A_R2__Guideline.pdf]."},{"key":"10.1016\/j.pharma.2019.04.005_bib0405","unstructured":"International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use: Q3B (R2). Impurities in new drug products. [Accessed June 2006]."},{"key":"10.1016\/j.pharma.2019.04.005_bib0410","series-title":"Quality control of herbal medicines and related areas","first-page":"25","article-title":"Stability indicating methods","author":"Cione","year":"2011"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450919300331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450919300331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:26:17Z","timestamp":1762086377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450919300331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0003450919300331"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2019.04.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a new stability indicating method for the simultaneous separation of voriconazole from its impurities along with sodium benzoate used as a preservative in a powder for oral suspension","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}